< Back to previous page
Researcher
Georg Halder
- Disciplines (Flanders Institute for Biotechnology):Analysis of next-generation sequence data, Cell death, Cancer biology
- Disciplines (KU Leuven):Morphological sciences, Oncology
- See also: Georg Halder (Flanders Institute for Biotechnology)
Affiliations
- Laboratory of Growth Control and Cancer Research (VIB-KU Leuven) (Division)
Responsible
From1 Jan 2017 → Today - Laboratory of Growth Control and Cancer Research (VIB-KU Leuven) (Division)
Member
From1 Jan 2017 → Today - Halder Lab (Research group)
Responsible
From1 Jan 2017 → Today - Department of Human Genetics (Department)
Member
From1 May 2012 → 31 Dec 2016
Projects
1 - 10 of 39
- Hippo Signaling in Lipid Metabolism: A Drosophila Approach to unravel Obesity ComplexitiesFrom2 Oct 2023 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Action of Hippo pathway inhibitors on liver cancer in miceFrom6 Sep 2023 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Action of Hippo pathway inhibitors on liver cancer in miceFrom5 Dec 2022 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Action of Hippo pathway inhibitors on liver cancer in miceFrom1 Nov 2022 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Hippo signaling pathway in liver cancer or liver regenerationFrom4 Oct 2022 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Understanding a novel tissue surveillance mechanism that suppresses liver cancerFrom11 May 2022 → TodayFunding: FWO fellowships
- Understanding the role of the Hippo pathway in chronic liver disease and liver cancerFrom15 Mar 2022 → 30 Aug 2023Funding: Own budget, for example: patrimony, inscription fees, gifts
- Exploring the Role of Endothelial-epithelial Mechanical Interactions in Shaping Mini-organsFrom27 Sep 2021 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Understanding the anti-cancer effects of new YAP/TAZ inhibitors to treat malignant mesotheliomaFrom1 Mar 2021 → TodayFunding: Foundations, funds and other with scientific goal
- Suppressing the evolution of liver cancer into highly aggressive formsFrom1 Mar 2021 → TodayFunding: Foundations, funds and other with scientific goal
Publications
11 - 20 of 58
- Novel antagonists of TEAD palmitoylation inhibit the growth of Hippo-altered cancers in preclinical models(2022)
Authors: Georg Halder
- The role of the actin cytoskeleton in the regulation of the Hippo pathway(2022)
Authors: Ruçhan Karaman, Georg Halder
- Initiation of hepatic stellate cell activation extends into chronic liver disease(2021)
Authors: Georg Halder
- A Mouse Model of Cholangiocarcinoma Uncovers a Role for Tensin-4 in Tumor Progression(2021)
Authors: Georg Halder
Pages: 1445 - 1460 - Regeneration Defects in Yap and Taz Mutant Mouse Livers Are Caused by Bile Duct Disruption and Cholestasis(2021)
Authors: Elisabeth Verboven, Ivan Moya, Jun Xie, Hanne Hillen, Weronika Kowalczyk, Gerlanda Vella, Stephanie Castaldo, Soheil Soheily, Diether Lambrechts, Tania Roskams, et al.
Pages: 847 - 862 - The Hippo pathway effectors YAP and TAZ induce cell competition to eliminate liver tumors through autophagy(2020)
Authors: Stephanie Castaldo, Georg Halder
- The role of Hippo signaling in liver regeneration(2020)
Authors: Elisabeth Verboven, Georg Halder
- Hippo signaling in liver regeneration and liver tumors.(2020)
Authors: Georg Halder
Pages: 14 - 14 - Yap activity in bile ducts, but not in hepatocytes, is required for normal liver regeneration.(2020)
Authors: Elisabeth Verboven, Ivan Moya, Georg Halder
Pages: 30 - 30 - Peritumoral activation of the Hippo pathway effectors YAP and TAZ suppresses liver cancer in mice(2019)
Authors: Ivan Moya, Stephanie Castaldo, Soheil Soheily, Jun Xie, Elisabeth Verboven, Hanne Hillen, Ruçhan Karaman, Matthias Van Haele, Weronika Kowalczyk, Panagiotis Karras, et al.
Pages: 1029 - 1034
Patents
1 - 2 of 2